• Explore /
  • Poster
  • / <i>KRAS</i> subset analysis from randomized phase II trials of erlotinib versus erlotinib plus sorafenib or pazopanib in refractory non-small cell lung cancer (NSCLC).

KRAS subset analysis from randomized phase II trials of erlotinib versus erlotinib plus sorafenib or pazopanib in refractory non-small cell lung cancer (NSCLC).

Abstract Poster

Authors

David Waterhouse

David Michael Waterhouse

Oncology Hematology Care/SCRI, Cincinnati, OH

David Michael Waterhouse , Dawn Michelle Stults , Davey B. Daniel , Paula L. Griner , F Anthony Greco , Howard A. Burris III, John D. Hainsworth , David R. Spigel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer - Non-small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT00600015; NCT01027598

Citation

J Clin Oncol 31, 2013 (suppl; abstr 8091)

DOI

10.1200/jco.2013.31.15_suppl.8091

Abstract #

8091

Poster Bd #

38G

Abstract Disclosures

Similar Posters

First Author: Karen L. Reckamp

First Author: Beth A. Hellerstedt

First Author: Li Zhang

First Author: Damien Vasseur